KURA Stock Recent News

Kura Oncology, Inc. has additional updated results released from the KOMET-001 study, as part of an oral late-breaker presentation shown on June 11, 2023 at the EHA; 35% achieved CR with full count recovery. The global Acute Myeloid Leukemia market is expected to reach $2.69 billion by 2028; 30% of AML patients have the NPM1 mutation and 5% to 10% have the KPT2A-rearranged mutation. KOMET-007 and KOMET-008 are two studies being launched two explore the synergistic effects of combining ziftomenib with other standard of care therapies for 1st line NPM1 and/or KMT2A-rearranged AML patients.

Kura Oncology (KURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Shares of Kura Oncology Inc. KURA, -1.24% dropped nearly 6% in the aftermarket Tuesday after the biotech said it plans to sell $100 million worth of shares, plus an option for underwriters to buy additional shares. Kura ended the regular trading day down 1.2%.

SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Pete De Spain - SVP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Thomas Doyle - SVP, Finance & Accounting Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Bradley Canino - Stifel, Nicolaus & Company Li Watsek - Cantor Fitzgerald & Co. Philip Nadeau - TD Cowen Operator Good afternoon, ladies and gentlemen, and welcome to the Q1 2023 Kura Oncology, Inc. Earnings Conference Call. [Operator Instructions].

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations and Corporate Communications Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Finance and Accounting Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Group LLC Peter Lawson - Barclays Li Watsek - Cantor Fitzgerald, L.P. Bradley Canino - Stifel Financial Corp. Eva Privitera - Cowen Inc. Reni Benjamin - JMP Securities LLC Operator Greetings, and welcome to Kura Oncology's Fourth Quarter 2022 Earnings Conference Call.

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology, Inc. has two assets, and both produced decent data. Each asset has its own set of problems.